ELIMED-ELIMAIA: The First Open User Irradiation Beamline for Laser-Plasma-Accelerated Ion Beams

Giuseppe A.P. Cirrone*, Giada Petringa, Roberto Catalano, Francesco Schillaci, Luciano Allegra, Antonino Amato, Renato Avolio, Michele Costa, Giacomo Cuttone, Antonin Fajstavr, Giuseppe Gallo, Lorenzo Giuffrida, Mariacristina Guarrera, Georg Korn, Giuseppina Larosa, Renata Leanza, Enzo Lo Vecchio, Gustavo Messina, Giuliana Milluzzo, Veronika OlsovcovaSalvatore Pulvirenti, Jan Pipek, Francesco Romano, Daniele Rizzo, Antonio D. Russo, S. Salamone, Valentina Scuderi, Andriy Velyhan, Salvatore Vinciguerra, Martina Zakova, Emilio Zappalà, Daniele Margarone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
32 Downloads (Pure)

Abstract

The main effort of the laser-driven ion acceleration community is aimed at improving particle beam features (in terms of final maximum energy, particle charge, and beam divergence) and to demonstrate reliable approaches for use for multidisciplinary applications. An ion acceleration target area based on unique laser capabilities is available at ELI-Beamlines (Extreme Light Infrastructure) in the Czech Republic; it is called ELIMAIA (ELI Multidisciplinary Applications of laser-Ion Acceleration) and aims to provide stable and characterized beams of particles accelerated by high-power lasers to offer them to the user community for interdisciplinary studies. The ELIMAIA section dedicated to ion focusing, selection, characterization, and irradiation is named ELIMED (ELI MEDical and multidisciplinary applications). Thanks to ELIMED, very high-dose-rate (around Gy/min) controlled proton and ion beams, with energy levels ranging from 5 to 250 MeV, will be transported to an in-air section dedicated to absolute and relative dosimetry of the laser-generated ions. A transmission dual-gap air ionization chamber will allow an on-line, non-destructive characterization of the ion dose at the user sample irradiation point. The uncertainty in the final dose released onto the sample is expected to be well below 5%. An ELIMED radiobiology pilot experiment is scheduled for 2021, during which in-vitro cell irradiations will be carried out with well-controlled proton beams. In this work, the status of the ELIMED/ELIMAIA beamline will be described along with a complete definition of the main dosimetric systems and of their calibrations carried out at conventional accelerators.

Original languageEnglish
Article number564907
Number of pages8
JournalFrontiers in Physics
Volume8
DOIs
Publication statusPublished - 13 Nov 2020

Bibliographical note

Funding Information:
Funding. This work has been supported by the project ELI?Extreme Light Infrastructure?phase 2 (CZ.02.1.01/0.0/0.0/15-008/0000162) from European Regional Development Fund, by the Ministry of Education, Youth and Sports of the Czech Republic (Project No. LQ1606) and by the project Advanced Research Using High Intensity Laser Produced Photons and Particles (CZ.02.1.01/0.0/0.0/16-019/0000789). This work has also been financially supported by the ELIMED INFN project.

Publisher Copyright:
© Copyright © 2020 Cirrone, Petringa, Catalano, Schillaci, Allegra, Amato, Avolio, Costa, Cuttone, Fajstavr, Gallo, Giuffrida, Guarrera, Korn, Larosa, Leanza, Lo Vecchio, Messina, Milluzzo, Olsovcova, Pulvirenti, Pipek, Romano, Rizzo, Russo, Salamone, Scuderi, Velyhan, Vinciguerra, Zakova, Zappalà and Margarone.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

  • dosimetry
  • ELIMED
  • laser-driven
  • laser-driven ions
  • Monte Carlo
  • protontherapy

ASJC Scopus subject areas

  • Biophysics
  • Materials Science (miscellaneous)
  • Mathematical Physics
  • Physics and Astronomy(all)
  • Physical and Theoretical Chemistry

Fingerprint

Dive into the research topics of 'ELIMED-ELIMAIA: The First Open User Irradiation Beamline for Laser-Plasma-Accelerated Ion Beams'. Together they form a unique fingerprint.

Cite this